Type 2 diabetes and cardiovascular disease: risk reduction and early intervention

References

• American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–S33.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Alguwaihes A, Arenas Leon JL, et al. CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes across 13 countries. Diabetologia. 2020;63(1):S1–S485. Abstract 158.
   PubMed Web of Science ®Google Scholar
• Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
   PubMed Web of Science ®Google Scholar
• Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(9):1117–1145.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–139.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111–S124.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [internet]. Ozempic prescribing information. 2020 [cited 2021 Jan 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
   Google Scholar
• US Food and Drug Administration [internet]. Trulicity prescribing information. 2020 [cited 2021 Jan 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf
   Google Scholar
• US Food and Drug Administration [internet]. Victoza prescribing information. 2020 [cited 2021 Jan 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s036lbl.pdf
   Google Scholar
• Vencio S, Alguwaihes A, Arenas Leon JL, et al. Contemporary use of diabetes medications with a cardiovascular indication in adults with type 2 diabetes: a secondary analysis of the multinational CAPTURE study. Diabetologia. 2020;63(1):S1–S485. Abstract 945.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Harris SB, Leiter LA, et al. Managing cardiometabolic risk in primary care: summary of the 2011 consensus statement. Can Fam Physician. 2012;58(4):389–393, e196–e201.
   Web of Science ®Google Scholar
• Verma S, Bain SC, Buse JB, et al. Occurrence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events: a post hoc analysis of a randomized clinical trial. JAMA Cardiol. 2019;4(12):1214–1220.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab. 2019;21(11):2576–2580.
   PubMed Web of Science ®Google Scholar
• Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209–E1215.
   PubMed Web of Science ®Google Scholar
• Arturi F, Succurro E, Miceli S, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2017;57(3):464–473.
   PubMed Web of Science ®Google Scholar
• Liakos A, Lambadiari V, Bargiota A, et al. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2019;21(3):517–524.
   PubMed Web of Science ®Google Scholar
• Matikainen N, Söderlund S, Björnson E, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84–94.
   PubMed Web of Science ®Google Scholar
• Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59(4):1030–1037.
   PubMed Web of Science ®Google Scholar
• Lim S, Lee GY, Park HS, et al. Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats. Cardiovasc Res. 2017;113(2):183–194.
   PubMed Web of Science ®Google Scholar
• Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567–575.
   PubMed Web of Science ®Google Scholar
• Bizino MB, Jazet IM, Westenberg JJM, et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):55.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–158.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–2055.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Benroubi M, Sun J-H, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241–2249.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–1246.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–230.
   PubMedGoogle Scholar
• Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409–418.
   PubMed Web of Science ®Google Scholar
• Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776–790.
   PubMed Web of Science ®Google Scholar
• Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014;7:107–120.
   PubMedGoogle Scholar
• Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563–574.
   PubMed Web of Science ®Google Scholar
• Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clin Diabetes. 2013;31(4):148–157.
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874–886.
   PubMed Web of Science ®Google Scholar
• Singh AK, Gangopadhyay KK, Singh R. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Rev Clin Pharmacol. 2020;13(4):461–468.
   PubMed Web of Science ®Google Scholar
• Abd El Aziz M, Cahyadi O, Meier JJ, et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22(4):699–704.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S125–S150.
   PubMed Web of Science ®Google Scholar
• Sperling LS, Mechanick JI, Neeland IJ, et al. The CardioMetabolic Health Alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050–1067.
   PubMed Web of Science ®Google Scholar
• American College of Cardiology/American Heart Association [internet]. ASCVD risk estimator plus. 2021 [cited 2021 Apr 12]. Available from: https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/
   Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144–S174.
   PubMed Web of Science ®Google Scholar
• Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol. 2011;10(1):13.
   PubMed Web of Science ®Google Scholar
• Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202–210.
   PubMedGoogle Scholar
• Esposito K, Ciotola M, Sasso FC, et al. Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. Nutr Metab Cardiovasc Dis. 2007;17(4):274–279. DOI:10.1016/j.numecd.2005.11.014.
   PubMed Web of Science ®Google Scholar
• Dickinson JK, Guzman SJ, Maryniuk MD, et al. The use of language in diabetes care and education. Diabetes Care. 2017;40(12):1790–1799.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• McGurnaghan S, Blackbourn LAK, Mocevic E, et al. Cardiovascular disease prevalence and risk factor prevalence in type 2 diabetes: a contemporary analysis. Diabet Med. 2019;36(6):718–725.
   PubMed Web of Science ®Google Scholar
• Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427–437.
   PubMed Web of Science ®Google Scholar
• Sasso FC, Pafundi PC, Simeon V, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol. 2021;20(1):145. DOI:10.1186/s12933-021-01343-1.
   PubMed Web of Science ®Google Scholar
• Weng W, Tian Y, Kong SX, et al. Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting. Clin Diabetes Endocrinol. 2020;6:5.
   PubMedGoogle Scholar
• Yang C-Y, Chen Y-R, H-T O, et al. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovasc Diabetol. 2021;20(1):21.
   PubMed Web of Science ®Google Scholar
• Tong L, Pan C, Wang H, et al. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database. Diabetes Obes Metab. 2018;20(4):831–839.
   PubMed Web of Science ®Google Scholar
• Blonde L, Raccah D, Lew E, et al. Treatment intensification in type 2 diabetes: a real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin. Diabetes Ther. 2018;9(3):1169–1184.
   PubMed Web of Science ®Google Scholar